Sapporo Medical University

www.web.sapmed.ac.jp
Sapporo, Japan

Sapporo Medical University is a public university in Chūō-ku, Sapporo, Hokkaidō, Japan. The precursor of the school was founded in 1945, and it was chartered as a university in 1950. Wikipedia.


Time filter

Source Type

[Problem] To activate an abnormal mesenchymal stem cell whose therapeutic effect is lost or reduced, or rather which has a disease-exacerbating effect so as to be in a state suitable for cell transplant therapy. [Solution] An activator for mesenchymal stem cells, mesenchymal stem cells activated by the activator, a method for producing the same, and a pharmaceutical containing the activated mesenchymal stem cells are provided.


[Problem to be Solved] To provide a device for rehabilitation capable of giving a patient who cannot express an intention to voluntarily move the body a kinesthetic illusion that the his/her own body is moving and thus achieving a high rehabilitation effect, a rehabilitation system including it, a program for rehabilitation, and a rehabilitation method. [Solution] The device for rehabilitation includes: a biological signal acquisition unit 71 that acquires biological signals from a patient imparted with illusory stimulation for inducing a kinesthetic illusion; a characteristic biological signal detection unit 72 that analyzes the biological signals and detects a characteristic biological signal indicating a state where the kinesthetic illusion is induced; and a control signal output unit 73 that outputs control signals for controlling body driving means 4 and/or brain simulating means 5, when the characteristic biological signal is detected.


The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.


[Problem] To activate an abnormal mesenchymal stem cell whose therapeutic effect is lost or reduced, or rather which has a disease-exacerbating effect so as to be in a state suitable for cell transplant therapy. [Solution] An activator for mesenchymal stem cells, mesenchymal stem cells activated by the activator, a method for producing the same, and a pharmaceutical containing the activated mesenchymal stem cells are provided.


Patent
Sapporo Medical University and Dainippon Sumitomo | Date: 2017-01-18

A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.


[Problem to be Solved] To provide a device for rehabilitation capable of giving a patient who cannot express an intention to voluntarily move the body a kinesthetic illusion that the his/her own body is moving and thus achieving a high rehabilitation effect, a rehabilitation system including it, a program for rehabilitation, and a rehabilitation method. [Solution] The device for rehabilitation includes: a biological signal acquisition unit 71 that acquires biological signals from a patient imparted with illusory stimulation for inducing a kinesthetic illusion; a characteristic biological signal detection unit 72 that analyzes the biological signals and detects a characteristic biological signal indicating a state where the kinesthetic illusion is induced; and a control signal output unit 73 that outputs control signals for controlling body driving means 4 and/or brain simulating means 5, when the characteristic biological signal is detected.


Patent
Sapporo Medical University, Medical and Biological Laboratories Co. | Date: 2017-08-02

The object is to provide a tumor antigen peptide that is specifically presented on a cancer and a cancer stem cell, and a pharmaceutical composition, etc. that is useful for the prevention and/or treatment of a cancer and contains the above peptide as an active ingredient. The above object has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, a polynucleotide encoding the peptide, a pharmaceutical composition containing the above as an active ingredient, and an agent for the prevention and/or treatment of a cancer, the agent containing the above as an active ingredient and inducing CTLs.


Hori Y.S.,Sapporo Medical University
PloS one | Year: 2013

Excessive reactive oxygen species (ROS) induce apoptosis and are associated with various diseases and with aging. SIRT1 (sirtuin-1), an NAD+-dependent protein deacetylase, decreases ROS levels and participates in cell survival under oxidative stress conditions. SIRT1 modulates the transcription factors p53, a tumor suppressor and inducer of apoptosis, and the forkhead O (FOXO) family, both of which play roles for cell survival and cell death. In this study, we aimed to know which is working greatly among p53 and FOXOs transcription factors in SIRT1's cell protective functions under oxidative stress conditions. The antimycin A-induced increase in ROS levels and apoptosis was enhanced by SIRT1 inhibitors nicotinamide and splitomicin, whereas it was suppressed by a SIRT1 activator, resveratrol, and a SIRT1 cofactor, NAD+. SIRT1-siRNA abolished the effects of splitomicin and resveratrol. p53-knockdown experiment in C2C12 cells and experiment using p53-deficient HCT116 cells showed that splitomicin and resveratrol modulated apoptosis by p53-dependent and p53-independent pathways. In p53-independent cell protective pathway, we found that FOXO1, FOXO3a, and FOXO4 were involved in SOD2's upregulation by resveratrol. The knockdown of these three FOXOs by siRNAs completely abolished the SOD2 induction, ROS reduction, and anti-apoptotic function of resveratrol. Our results indicate that FOXO1, FOXO3a and FOXO4, are indispensable for SIRT1-dependent cell survival against oxidative stress, although deacetylation of p53 has also some role for cell protective function of SIRT1.


Patent
The Chemo Sero Therapeutic Research Institute, Tokyo Medical, Dental University, Sapporo Medical University and Adeka Corporation | Date: 2016-03-16

A hybrid gel comprising a particulate decellularized tissue (obtained by pulverizing animal-derived biological tissues that are decellularized (decellularized biological tissues)), fibrinogen and thrombin; a cell culture material comprising the hybrid gel; a method for preparing the hybrid gel; and a kit comprising a particulate decellularized tissue and a biological tissue adhesive are provided. The hybrid gel of the present invention exerts the effect to promote differentiation and gain of function of stem cells and the therapeutic effect to a variety of diseases.


Patent
Dainippon Sumitomo and Sapporo Medical University | Date: 2016-08-10

The purpose of the present invention is to provide: a detection agent for specifically detecting cancer stem cells; a tumor antigen peptide specifically exhibited by cancer stem cells; a pharmaceutical composition for the prevention and/or treatment of cancer, containing same as an effective component thereof; and a method for screening said tumor antigen peptide. A peptide indicated by YO-XO-ZO, a polyepitope peptide including at least one said peptide as an epitope peptide and having a plurality of epitope peptides joined therein, a polynucleotide that codes at least either the peptide or the polyepitope peptide, a pharmaceutical composition containing these as an effective component thereof, and a cancer prevention and/or treatment agent characterized by inducing CTLs.

Loading Sapporo Medical University collaborators
Loading Sapporo Medical University collaborators